Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Clinical Trial
94%
Malignant Neoplasm
93%
Solid Malignant Neoplasm
88%
Advanced Cancer
80%
Diseases
70%
Adverse Event
44%
Phase I Trials
36%
Overall Survival
36%
Pembrolizumab
33%
Bevacizumab
30%
Maximum Tolerated Dose
30%
Progression Free Survival
30%
Paclitaxel
25%
Immune Checkpoint Inhibitor
25%
Immunotherapy
24%
Pharmacokinetic
20%
Selinexor
19%
Antitumor Activity
19%
Non Small Cell Lung Cancer
18%
Temsirolimus
18%
Colorectal Carcinoma
17%
Melanoma
17%
Mammalian Target of Rapamycin Inhibitor
16%
Chemotherapy
16%
Combination Therapy
16%
Epidermal Growth Factor Receptor
15%
Thrombocytopenia
15%
Vasculotropin
15%
Carboplatin
15%
Monotherapy
14%
Pharmacodynamics
13%
Prevalence
12%
Diarrhea
12%
Oxaliplatin
11%
Metastasis
11%
Sorafenib
10%
Tolerability
10%
Cetuximab
10%
Connective Tissue Cancer
10%
Neutropenia
9%
Liver Metastasis
9%
Pazopanib
9%
Breast Cancer
9%
Ovary Cancer
9%
Lenalidomide
9%
Biological Marker
9%
Rash
8%
Anemia
8%
Nausea
8%
Keyphrases
Patients with Advanced Cancer
58%
Stable Disease
53%
Phase I Clinical Trial
51%
Advanced Solid Tumors
49%
Phase I Trial
43%
Partial Response
43%
Pembrolizumab
37%
MD Anderson Cancer Center
36%
Phase I Study
33%
Immune Checkpoint Inhibitors
30%
Bevacizumab
27%
Center Experience
27%
Early Phase Clinical Trials
25%
Confidence Interval
23%
Dose-limiting Toxicity
23%
Tumor
21%
Clinical Outcomes
21%
Advanced Malignancies
21%
Maximum Tolerated Dose
21%
PIK3CA mutation
20%
Targeted Therapy
20%
Non-small Cell Lung Cancer (NSCLC)
19%
Overall Survival
19%
MTOR Inhibitor
19%
Selinexor
18%
Temsirolimus
17%
Paclitaxel
16%
Antitumor Activity
16%
Mammalian Target of Rapamycin (mTOR)
15%
Clinical Benefit
15%
Programmed Death-ligand 1 (PD-L1)
15%
Dose Level
15%
Progression-free Survival
15%
Tumor Subtype
15%
Advanced Cancer
15%
Solid Tumors
15%
Clinical Trials
15%
Monotherapy
14%
Treatment-related Adverse Events
14%
Adverse Events
13%
Dose-escalation Study
13%
In Cancer
13%
Complete Response
12%
Median Overall Survival
12%
Thrombocytopenia
12%
Dose Escalation
12%
Metastatic Tumor
12%
Royal
12%
Cancer Patients
12%
Immune-related Adverse Events
12%
Medicine and Dentistry
Clinical Trial
78%
Malignant Neoplasm
68%
Neoplasm
65%
Diseases
50%
Advanced Cancer
49%
Cancer
46%
Targeted Therapy
31%
Overall Survival
30%
Progression Free Survival
29%
Immune Checkpoint Inhibitor
26%
Pembrolizumab
26%
Solid Malignant Neoplasm
25%
Immunotherapy
24%
Phase I Trials
20%
Mammalian Target of Rapamycin Inhibitor
17%
Adverse Event
15%
Non Small Cell Lung Cancer
14%
Melanoma
14%
Immunity
14%
Biological Marker
13%
Metastatic Carcinoma
13%
Mammalian Target of Rapamycin
12%
Colorectal Carcinoma
12%
Prevalence
12%
Oncology
12%
Systemic Therapy
12%
Adrenal Cortex Carcinoma
10%
Connective Tissue Cancer
10%
Immune-Related Adverse Events
9%
Temsirolimus
9%
Next Generation Sequencing
9%
Ewing Sarcoma
9%
Pneumonia
9%
Combination Therapy
9%
Epidermal Growth Factor Receptor
9%
Selinexor
9%
Ovarian Cancer
9%
PI3K/AKT/mTOR Pathway
9%
Hazard Ratio
8%
Multivariate Analysis
8%
Squamous Cell Carcinoma
8%
Bevacizumab
8%
Thrombocytopenia
8%
Paclitaxel
7%
Patient Referral
7%
Rapamycin
7%
Cixutumumab
7%
Somatomedin
7%
Carboplatin
7%
T Cell
6%